NCT03174990 is a clinical trial in Peripheral Arterial Disease, sponsored by University of California, Davis.

Who is sponsoring NCT03174990?

NCT03174990 is sponsored by University of California, Davis.

What condition does NCT03174990 study?

NCT03174990 studies Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of.

Is NCT03174990 still recruiting?

NCT03174990 is currently completed. Last updated 5 June 2017.

Last reviewed 2017-06-05 · How we verify

NCT03174990

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

Completed Last updated 5 June 2017

What this trial tests

trial in Peripheral Arterial Disease in 195 participants. Completed in 20 December 2013.

Timeline

31 August 2010

Primary endpoint
17 May 2013

20 December 2013

Quick facts

Lead sponsor	University of California, Davis
Status	Completed
Study type	OBSERVATIONAL
Enrollment	195
Start date	31 August 2010
Primary completion	17 May 2013
Estimated completion	20 December 2013
Sites	1 location across United States

Conditions studied

Peripheral Arterial Disease — all drugs for Peripheral Arterial Disease →
Clopidogrel, Poor Metabolism of — all drugs for Clopidogrel, Poor Metabolism of →

Sponsor

University of California, Davis

Who can join

18 and older, any sex, with Peripheral Arterial Disease or Clopidogrel, Poor Metabolism of. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in patients with peripheral arterial disease (PAD) currently remain unknown.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
Yeo KK, Armstrong EJ, López JE, Chen DC, et al · · 2018 · cited 15× · PMID 29411531 · DOI 10.1002/ccd.27453

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

NCT05437562 — Randomized Clinical Trial for Ewing Amputation in the VA · NA · recruiting
NCT07427108 — Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety · NA · recruiting
NCT07336381 — Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy · NA · recruiting
NCT07076082 — Vascular Trial Associated Registry Pilot · Phase 4 · recruiting
NCT06308562 — Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease · NA · recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03174990 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 5 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03174990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing